Collaboration Models
Our Strength
Our Partner
Collabration Areas

Areas of Collaboration

Asieris aims to become a specialty pharmaceutical company in urology and urogenital cancers. Our leading drugs APL-1202 and APL-1301 are the first oral drugs in the world for the treatment of non-muscular-invasive bladder cancer, (NMIBC) and are expected to shift the current treatment paradigm for NMIBC. In addition to such breakthrough drugs, we possess a strong team of research and clinical experts to support drug optimization and to advance our clinical programs in China. We will continue to develop high quality, novel drugs internally, and supplemented with in-licensing or alliance to further enrich our product portfolio.

Besides clinical research, we have also established proprietary R&D platforms. We have established animal models for identifying drugs with novel anti-cancer mechanism of action. We are also conducting research for identifying drugs with novel immuno-regulatory properties.

We hope to collaborate with the world's leading research institutions in the areas below, and are confident that you will find Asieris your best partner.

      • Therapeutic Areas:
- Oncology, especially Genito-urinary oncology
      - Urological diseases
      - Multidrug-resistance infections

       "Drug Repositioning" Technologies
- Novel mechanisms that can be rapidly validated with "old drugs" in clinical trials
      - Technology platforms to screen "old drugs" for new mechanisms of action
      - Technology platforms for special deliveries of "old drugs"